Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.50 |
| ▸ | NPY1R | P25929 | 11/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.50 |
| ▸ | NPY2R | P49146 | 7/20 | 0.50 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185394 | 0.93 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30571037 | 0.88 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL30098797 | 0.88 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL27584151 | 0.87 | NMT2 (0.38) | NMT2NMT1 | |
| SCHEMBL2183030 | 0.87 | NMT2 (0.38) | NMT2NMT1 | |
| SCHEMBL16468902 | 0.87 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL16497315 | 0.85 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11011211 | 0.84 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11011199 | 0.84 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL10378723 | 0.84 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | NPY4R 567/4885NPY1R 544/4885NPY5R 588/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | NPY4R 2480/4885NPY1R 3329/4885NPY5R 3577/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | NPY4R 2480/4885NPY1R 3329/4885NPY5R 3577/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | NPY4R 915/4885NPY1R 631/4885NPY5R 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.